Efficacy of the echinocandin caspofungin against disseminated aspergillosis and candidiasis in cyclophosphamide-induced immunosuppressed mice
about
Role of molecular mimicry of hepatitis C virus protein with platelet GPIIIa in hepatitis C-related immunologic thrombocytopeniaIn vitro activity of caspofungin against Candida albicans biofilms.Early-onset heparin-induced thrombocytopenia after a 165-day heparin-free interval: case report and review of the literature.Caspofungin inhibits Rhizopus oryzae 1,3-beta-D-glucan synthase, lowers burden in brain measured by quantitative PCR, and improves survival at a low but not a high dose during murine disseminated zygomycosis.Candida infections of the genitourinary tract.Caspofungin susceptibility testing of isolates from patients with esophageal candidiasis or invasive candidiasis: relationship of MIC to treatment outcomeSpecific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates.Quantitative PCR assay to measure Aspergillus fumigatus burden in a murine model of disseminated aspergillosis: demonstration of efficacy of caspofungin acetate.Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia.Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases.Effect of the echinocandin caspofungin on expression of Candida albicans secretory aspartyl proteinases and phospholipase in vitroProtection of killer antiidiotypic antibodies against early invasive aspergillosis in a murine model of allogeneic T-cell-depleted bone marrow transplantationPharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity.A clinical perspective for the management of invasive fungal infections: focus on IDSA guidelines. Infectious Diseases Society of America.Caspofungin: pharmacology, safety and therapeutic potential in superficial and invasive fungal infections.Aspergillus fumigatus cell wall: composition and biosynthesis.Interaction between posaconazole and caspofungin in concomitant treatment of mice with systemic Aspergillus infection.Evaluation of broth microdilution testing parameters and agar diffusion Etest procedure for testing susceptibilities of Aspergillus spp. to caspofungin acetate (MK-0991).Strategies to prevent, treat, and provoke Corynebacterium-associated hyperkeratosis in athymic nude mice.Caspofungin: first approved agent in a new class of antifungals.Efficacy of caspofungin against Aspergillus flavus, Aspergillus terreus, and Aspergillus nidulansPharmacodynamics of echinocandins against Candida glabrata: requirement for dosage escalation to achieve maximal antifungal activity in neutropenic hostsSystemic antifungal therapy: new options, new challenges.New and emerging antifungal agents: impact on respiratory infections.Concentration-dependent effects of caspofungin on the metabolic activity of Aspergillus species.The yeast protein kinase C cell integrity pathway mediates tolerance to the antifungal drug caspofungin through activation of Slt2p mitogen-activated protein kinase signaling.Clinical impact of the fungicidal activity of caspofungin administered alone or in combination in critically ill patients with severe abdominal candidiasis refractory to conventional antifungal drugs: case studies and critical review of the problem.Pharmacological properties and clinical efficacy of a recently licensed systemic antifungal, caspofungin.Micafungin in the treatment of candiduria: A case series.The echinocandins: comparison of their pharmacokinetics, pharmacodynamics and clinical applications.The pharmacology and clinical use of caspofungin.Caspofungin modulates inflammatory responses to Aspergillus fumigatus through stage-specific effects on fungal beta-glucan exposure.Disparate proteome responses of pathogenic and nonpathogenic aspergilli to human serum measured by activity-based protein profiling (ABPP).Stage-specific innate immune recognition of Aspergillus fumigatus and modulation by echinocandin drugs.Need for early antifungal treatment confirmed in experimental disseminated Candida albicans infection.Preclinical Pharmacokinetics and Pharmacodynamic Target of SCY-078, a First-in-Class Orally Active Antifungal Glucan Synthesis Inhibitor, in Murine Models of Disseminated Candidiasis.Emergence of Candida spp. and exploration of natural bioactive molecules for anticandidal therapy--status quo.Echinocandins: are they all the same?Discovery and development of first in class antifungal caspofungin (CANCIDAS®)--a case study.In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp.
P2860
Q27488342-E510A91C-AB3E-4DCA-8B6C-5050A3E3D3D4Q31114513-C252DA6A-BDDD-41DC-ADE0-8E068A271597Q33366929-0CBA2E18-1986-4F55-B039-E5FAAFF3219FQ33805542-B56C2946-EB22-49AF-AFEB-5EBEC942E0A2Q33825621-18522DC5-3AE4-44EF-A8DD-D9B4B26B4510Q33935389-9CAF5E13-D3F4-4824-A3FD-EF20CE818077Q33938068-B16059BC-5532-4E48-88D5-F7AA01B262D1Q33983618-349B1376-C459-4099-A3F4-1B42B9985E8CQ34104748-FCF51868-50FA-4191-8EBA-AA818FFB5586Q34105475-E108737E-49F6-4F7F-865B-D7E61625AF10Q34112321-47AFD1AC-1DA5-43E3-ABF7-2EB1D4BDD6EFQ34121622-14D4B575-1394-496A-ADD0-DC74E6A512B4Q34228214-B52373A4-E461-4D0E-B1D6-F6DDCE590B1BQ34335250-E5CF3675-BC6D-4C49-8E49-77252E6EFEA4Q34481664-2A53AF75-54D7-452A-B835-5CC5F84675D9Q34500213-384D444A-326B-4482-B29C-A1A3BB00A193Q34721750-88BE61A9-934B-4803-B564-ACEDD766535DQ34749364-2D7D3933-9236-49BE-B79D-FB61F4ADA923Q35010826-44D7A18D-325A-4DEA-986E-B1DCC054C029Q35124726-19DD1648-4729-48EF-9532-00319C73E9A6Q35215384-B7530922-128D-407F-992A-1B577490D684Q35270758-8F2DA4EB-33B9-4CAA-9DB4-8EBE15C01F23Q35585219-2C04DD22-F600-4EA9-A839-3BF752AB443FQ35627629-6C264EC3-5ED8-4842-90D8-69A255CB7AAEQ35647724-40BFF69E-F45D-41E9-BE66-9FC6A926EEFBQ35697550-C0965AD6-E43E-408C-8F16-F8CB0571105AQ35738800-90F9A8E4-111B-47BA-9CF6-7D0E9F961246Q36176371-DC6C98DC-75A2-4831-9E7F-F0A9DD03AA49Q36577831-6A909B94-B80B-4C87-8DA8-B42C5731BA26Q36626518-8673FFF3-C043-4A02-AE3C-C7FB0F6CE279Q36788428-FD0B29AF-4FB9-45FA-9101-EBD3C1F74B19Q36983268-E7CB56FB-F051-40F7-9A1C-1E8B76222F2FQ37001955-ACFD4CB2-7CFD-40A0-B177-F6089615E71EQ37209970-74B1DDBE-CFA8-4890-A9C9-68B8D125DCAEQ37625016-919BFD64-4885-4425-B4A2-CE74B9204FE0Q37720794-0D9146D7-D0BF-42A6-A62E-1B8B09051A0CQ37961230-4CB6CDE4-D2D9-4543-9740-EC0D63B80DFCQ37974743-C33156CD-FB5B-4516-BFCB-47BBEDAD51F2Q38165714-BDDDFFB6-29BF-4A87-912B-9B8F8F188BF8Q39651019-1097320C-90FC-4634-9758-2A5BD0C96C5F
P2860
Efficacy of the echinocandin caspofungin against disseminated aspergillosis and candidiasis in cyclophosphamide-induced immunosuppressed mice
description
2000 nî lūn-bûn
@nan
2000 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Efficacy of the echinocandin c ...... -induced immunosuppressed mice
@ast
Efficacy of the echinocandin c ...... -induced immunosuppressed mice
@en
Efficacy of the echinocandin c ...... -induced immunosuppressed mice
@nl
type
label
Efficacy of the echinocandin c ...... -induced immunosuppressed mice
@ast
Efficacy of the echinocandin c ...... -induced immunosuppressed mice
@en
Efficacy of the echinocandin c ...... -induced immunosuppressed mice
@nl
prefLabel
Efficacy of the echinocandin c ...... -induced immunosuppressed mice
@ast
Efficacy of the echinocandin c ...... -induced immunosuppressed mice
@en
Efficacy of the echinocandin c ...... -induced immunosuppressed mice
@nl
P2093
P2860
P1476
Efficacy of the echinocandin c ...... -induced immunosuppressed mice
@en
P2093
A M Flattery
C Leighton
G K Abruzzo
K Bartizal
V B Pikounis
P2860
P304
P356
10.1128/AAC.44.9.2310-2318.2000
P407
P577
2000-09-01T00:00:00Z